These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17409981)

  • 1. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
    Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
    J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
    Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
    Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
    Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
    J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
    Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
    J Thorac Oncol; 2006 Nov; 1(9):1010-9. PubMed ID: 17409987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update.
    Read W; McLeod H; Govindan R
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
    Natale RB; Socinski M; Sandler A; Israel VP; Miller L
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):29-34. PubMed ID: 10981288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Spigel DR; Hainsworth JD; Simons L; Meng C; Burris HA; Yardley DA; Grapski R; Schreeder M; Mallidi PV; Greco FA;
    J Thorac Oncol; 2007 Sep; 2(9):854-61. PubMed ID: 17805064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
    Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
    Murren JR; Andersen N; Psyrri D; Brandt D; Nadkarni R; Rose M; Davies MJ; Parisot N; Rosenfield AT; Pizzorno G; Zelterman D
    Cancer Biol Ther; 2005 Dec; 4(12):1311-5. PubMed ID: 16258263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
    Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
    J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer.
    Govindan R; Read W; Faust J; Mc Leod H
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):27-9. PubMed ID: 12886871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
    J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
    Han JY; Lee DH; Lee SY; Park CG; Kim HY; Lee HG; Lee JJ; Kim HT; Lee JS
    Cancer; 2005 Dec; 104(12):2759-65. PubMed ID: 16294344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.